Loading…
Indivior Pharmaceuticals, Inc. is projected to rise to $59.22 by 2027, a +47% move from its current price of $40.22. INDV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $39.65 | $40.25 | $40.86 | +0.08% |
| Aug 2 | $39.44 | $40.29 | $41.15 | +0.17% |
| Aug 3 | $39.28 | $40.32 | $41.38 | +0.25% |
| Aug 4 | $39.16 | $40.35 | $41.59 | +0.33% |
| Aug 5 | $39.05 | $40.39 | $41.77 | +0.41% |
| Aug 6 | $38.96 | $40.42 | $41.94 | +0.50% |
| Aug 7 | $38.88 | $40.45 | $42.10 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $38.88 | $40.45 | $42.10 | +0.58% |
| Week 2 | $38.46 | $40.69 | $43.04 | +1.17% |
| Week 3 | $38.20 | $40.93 | $43.85 | +1.75% |
| Week 4 | $38.01 | $41.16 | $44.57 | +2.35% |
| Week 5 | $37.88 | $41.40 | $45.26 | +2.94% |
| Week 6 | $37.78 | $41.64 | $45.91 | +3.54% |
| Week 7 | $37.70 | $41.89 | $46.54 | +4.14% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Indivior Pharmaceuticals, Inc. engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.
The company was formerly known as Indivior PLC and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc. (INDV) is a healthcare company focused on buprenorphine-based treatments for opioid use disorder and related conditions. Its stock currently trades with a price of $40.53 and a market cap of $4.79B, and it is ranked 1317 by market capitalization.
The current price is supported by a near-term technical setup and a forecast that shows a multi-year upside path. The 2026 forecast depicts a neutral start around the current level, with substantial upside potential unfolding in subsequent years.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 4.0% above — a clean break opens room to run.
A major ceiling 9.1% above — clearing it would confirm fresh momentum.
Key INDV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INDV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.37 | Sell | $40.33 | Sell |
| MA 10 | $40.29 | Sell | $40.36 | Sell |
| MA 20 | $40.41 | Sell | $40.23 | Sell |
| MA 50 | $39.06 | Buy | $39.09 | Buy |
| MA 100 | $36.18 | Buy | $37.15 | Buy |
| MA 200 | $34.39 | Buy | $33.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.47 | Neutral |
| Stoch RSI (14) | 41.37 | Neutral |
| CCI (20) | -35.41 | Neutral |
| Williams %R (14) | -41.18 | Info |
| MACD (12,26,9) | -0.13 | Sell |
| ROC (12) | -0.02 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 58.82 | Neutral |
| TRIX (15) | 0.16 | Buy |
| Awesome (5,34) | 0.29 | Buy |
| Ultimate (7,14,28) | 47.73 | Neutral |
| Momentum (10) | -0.37 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 40.40 | Sell |
| ADX (14) | 13.56 | Neutral |
| ATR (14) | 0.51 | Info |
The near-term technical picture remains bullish overall, with RSI(14) listed at 50 and moving averages showing breadth: SMA(50) at $38.77 and SMA(200) at $33.97. Key intraday levels place support at $37.93 and resistance at $41.83, framing a constructive bias around the current area. The 30-day price range spans $36.56 to $44.92, indicating a consolidating range around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.78 | $40.22 | $56.43 | 0% | Neutral | |
| $48.56 | $59.22 | $75.47 | +47% | Bullish | |
| $64.34 | $79.97 | $104.72 | +99% | Bullish | |
| $76.67 | $96.77 | $129.44 | +141% | Bullish | |
| $82.10 | $105.03 | $143.04 | +161% | Bullish | |
| $95.87 | $124.15 | $171.77 | +209% | Bullish | |
| $110.06 | $144.15 | $202.29 | +258% | Bullish | |
| $128.91 | $170.62 | $242.55 | +324% | Bullish | |
| $158.87 | $212.36 | $305.52 | +428% | Bullish | |
| $177.76 | $239.88 | $348.96 | +496% | Bullish | |
| $296.69 | $417.61 | $636.73 | +938% | Bullish | |
| $592.80 | $894.96 | $1,462.88 | +21.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.78 | $40.22 | $46.88 | +0.00% |
| August 2026 | $36.35 | $42.38 | $50.36 | +5.38% |
| September 2026 | $36.99 | $43.37 | $52.03 | +2.34% |
| October 2026 | $36.72 | $43.26 | $52.28 | -0.26% |
| November 2026 | $37.53 | $44.38 | $53.96 | +2.59% |
| December 2026 | $38.91 | $46.17 | $56.43 | +4.02% |
Click any year to see its month-by-month INDV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect INDV to range from $28.78 to $56.43 through 2026. The $40.22 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The INDV price prediction for 2027 points to an average of $59.22 (low $48.56, high $75.47) — a potential gain of +47% on today's $40.22. Buyers look set to stay in control over this stretch.
In 2028, INDV is projected to trade between $64.34 and $104.72, averaging $79.97 — a potential gain of +99% from today's $40.22. That is up +35% on the projected 2027 average. Momentum favours further upside here.
Indivior Pharmaceuticals, Inc.'s 2029 outlook centres on $96.77, within a $76.67 to $129.44 range. That is up +21% on the projected 2028 average. That marks a +141% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, INDV could reach as high as $143.04, with a base case around $105.03 and support toward $82.10 — roughly +161% from $40.22. Momentum favours further upside here.
Expect INDV to range from $95.87 to $171.77 through 2031. The $124.15 average target implies a +209% move from current prices. That is up +18% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The INDV price prediction for 2032 points to an average of $144.15 (low $110.06, high $202.29) — a potential gain of +258% on today's $40.22. Momentum favours further upside here.
In 2033, INDV is projected to trade between $128.91 and $242.55, averaging $170.62 — a potential gain of +324% from today's $40.22. That is up +18% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Indivior Pharmaceuticals, Inc.'s 2034 outlook centres on $212.36, within a $158.87 to $305.52 range. That is up +24% on the projected 2033 average. That marks a +428% change versus current levels. Momentum favours further upside here.
By 2035, INDV could reach as high as $348.96, with a base case around $239.88 and support toward $177.76 — roughly +496% from $40.22. Buyers look set to stay in control over this stretch.
Expect INDV to range from $296.69 to $636.73 through 2040. The $417.61 average target implies a +938% move from current prices. That is up +74% on the projected 2035 average. Momentum favours further upside here.
The INDV price prediction for 2050 points to an average of $894.96 (low $592.80, high $1,462.88) — a potential gain of +21.3x on today's $40.22. Buyers look set to stay in control over this stretch.
Investing $1,000 in INDV today (≈ 24.863252 INDV) could be worth
$22,251.7
+$21,251.7 (+2125%) by 2050 · US Dollar
Based on the average projected INDV price of $894.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INDVwould be worth at today's price.
$1,000 invested in INDV on Jul 30, 2025 (≈ 57.471266 INDV) would be worth
$2,311.49
+$1,311.49 (+131.1%) today · 2.31× · US Dollar
Based on a INDV entry price of $17.4 vs. today's $40.22.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $40.51 | $992.84 | -0.7% |
| 1 month ago | $41.03 | $980.26 | -2.0% |
| 3 months ago | $37.66 | $1,067.98 | +6.8% |
| 6 months ago | $35.38 | $1,136.8 | +13.7% |
| 1 year ago | $17.4 | $2,311.49 | +131.1% |
| All time (5.0y) ago | $11.3 | $3,559.29 | +255.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INDV forecast.
Our base-case forecast reaches $80.00 around 2029.
Implied market cap at $80.00: $9.46B
The multi-year forecast shows a clear upshift in the price path after 2026. For 2026 the min, avg, and max are $28.78, $40.53, and $57.08 with ROI 0 and sentiment NEUTRAL. By 2027 the forecast rises to an avg of $59.74 (min $48.97, max $76.17) and ROI 47.4 with a BULLISH stance; 2028 lists an avg of $81.02 (min $65.18, max $106.13) and ROI 99.9; 2029 shows avg $97.68 (min $77.38, max $130.70) and ROI 141.
The path extends to 2030 with an avg of $105.59 (min $82.52, max $143.84) and ROI 160.6; 2031–2035 continues the bullish trajectory with increasingly higher implied prices and ROIs (e.g., 2031 avg $125.92, ROI 210.7; 2032 avg $145.67, ROI 259.4; 2033 avg $171.29, ROI 322.7; 2034 avg $215.07, ROI 430.7; 2035 avg $242.34, ROI 498). The forecast then accelerates further to 2040 avg $423.37 (min $300.75, max $645.59) with ROI 944.7 and 2050 avg $901.06 (min $596.79, max $1,472.97) with ROI 2123.5. Sentiment remains BULLISH across the longer horizon.
These figures are estimates and not guarantees, reflecting modeled paths given current data and assumptions.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $105.59 with a min of $82.52 and a max of $143.84, and a projected ROI of 160.6% with a BULLISH sentiment.
The long-term outlook is bullish with substantial upside shown in years like 2027–2050 (e.g., 2030 avg $105.59 and 2050 avg $901.06, ROI 160.6% and 2123.5% respectively). However, the 2026 forecast is neutral with an avg near $40.53 and ROI 0%, so outcomes are estimates and not guarantees.
Yes. The 2030 forecast lists an average price of $105.59 and a max of $143.84, indicating potential to reach and exceed $100 based on the forecast path.
Current price is $40.53 and market cap is $4.79B.
The 30-day range spans from $36.56 to $44.92.
Indivior Pharmaceuticals, Inc. Community Discussion
0Share your Indivior Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.